Efficacy and Safety of Covid-19 Vaccine in Cardiac Patients

NCT ID: NCT05348629

Last Updated: 2022-04-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-01

Study Completion Date

2023-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Efficacy and safety of covid-19 vaccine in Cardiac patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

investigate the efficacy and safety of covid-19 vaccine in cardiac patients and its possible assocciated morbidity

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Vaccine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects diagnosed as STEMI undergo PPCI as (Fourth universal definition of myocardial infarction (2018) Kristian Thygesen) 10
* with age range from 18 to 80 years after 1 month of STEMI .

Exclusion Criteria

* Patients with previous covid infection confirmed by swap or CT chest or ICU addmision.
* Patients with previous covid infection confirmed by qualitative antibdy test .
* Patients with history of anaphylaxis to any component of the vaccine should not take it .
* patients with febrile illness or acute , ongoing infection .
* immunosuppressive diseases .
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role collaborator

Mina sobhi said fam

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mina sobhi said fam

resident doctor

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assiut University

Asyut, , Egypt

Site Status RECRUITING

Assiut university

Asyut, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mina Fam, Residuant

Role: CONTACT

+201122035368

Aly Tohamy, Lecturer

Role: CONTACT

+201006258877

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mina Fam, Resident

Role: primary

+201122035368

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

covid-19 vaccine

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

COVID-19 Echo Study
NCT05317962 COMPLETED